Cannara Biotech Inc Cash Flow Conversion Efficiency

Latest as of November 2025: 0.072x

Cannara Biotech Inc cash flow conversion efficiency. Based on the latest financial reports, Cannara Biotech Inc (LOVE) has a cash flow conversion efficiency ratio of 0.072x as of November 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$7.96 Million ≈ $5.76 Million USD) by net assets (CA$111.21 Million ≈ $80.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Cannara Biotech Inc (2018–2025)

Cash flow conversion efficiency of Cannara Biotech Inc from 2018 to 2025. This chart illustrates how Cannara Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cannara Biotech Inc stock quote for real-time trading data and today's change.

Cannara Biotech Inc Cash Flow Conversion Ratio Explained

Cannara Biotech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Cannara Biotech Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cannara Biotech Inc ranked by their cash flow conversion efficiency. Also see LOVE market cap for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Business Online PCL BK:BOL	0.012x
Bokusgruppen AB ST:BOKUS	-0.040x
Long Bon International Co Ltd TW:2514	-0.003x
HYUNDAI FEED Inc KQ:016790	0.015x
Signpost India Limited NSE:SIGNPOST	0.047x
Shandong Jining Ruyi Woolen Textile Co Ltd SHE:002193	-0.014x
ENIGMATIG LIMITED NYSE MKT:EGG	0.008x
Midas Minerals Ltd AU:MM1	-0.189x

Annual Cash Flow Conversion Efficiency for Cannara Biotech Inc (2018–2025)

The table below shows the annual cash flow conversion efficiency of Cannara Biotech Inc from 2018 to 2025. Review Cannara Biotech Inc free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-08-31	CA$102.22 Million ≈ $73.95 Million	CA$20.01 Million ≈ $14.48 Million	0.196x	+61.19%
2024-08-31	CA$87.95 Million ≈ $63.62 Million	CA$10.68 Million ≈ $7.73 Million	0.121x	+63.86%
2023-08-31	CA$79.74 Million ≈ $57.69 Million	CA$5.91 Million ≈ $4.28 Million	0.074x	+181.38%
2022-08-31	CA$66.74 Million ≈ $48.28 Million	CA$-6.08 Million ≈ $-4.40 Million	-0.091x	-179.05%
2021-08-31	CA$64.12 Million ≈ $46.38 Million	CA$-2.09 Million ≈ $-1.51 Million	-0.033x	+86.57%
2020-08-31	CA$38.36 Million ≈ $27.75 Million	CA$-9.32 Million ≈ $-6.75 Million	-0.243x	-63.78%
2019-08-31	CA$49.93 Million ≈ $36.12 Million	CA$-7.41 Million ≈ $-5.36 Million	-0.148x	+5.07%
2018-08-31	CA$14.74 Million ≈ $10.66 Million	CA$-2.30 Million ≈ $-1.67 Million	-0.156x	--

About Cannara Biotech Inc

V:LOVE Canada Drug Manufacturers - Specialty & Generic

Market Cap

$126.80 Million

CA$175.28 Million CAD

Market Cap Rank

#18121 Global

#590 in Canada

Share Price

CA$1.83

Change (1 day)

-2.14%

52-Week Range

CA$1.58 - CA$1.98

All Time High

CA$3.05